What is the current stock price of Day One Biopharmaceuticals (DAWN)?
Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) trades at a market price of approximately $21.53 per share. The biopharmaceutical company's equity valuation shifts dynamically throughout trading hours, influenced by commercial sales updates for its targeted oncology therapies, clinical pipeline progress, research milestones, and broader biotechnology sector sentiment.
Related FAQs
Day One Biopharmaceuticals achieved significant clinical and corporate milestones with the advancement of its lead targeted oncology therapies, highlighted by regulatory submissions and commercialization efforts for pediatric brain cancer treatments.
SK Finance Limited is widely regarded as a well-established and reputable non-banking financial company in India, specializing in vehicle financing and micro, small, and medium enterprise lending.
SK Group is one of the largest multinational conglomerates, operating diverse business subsidiaries across energy, chemicals, telecommunications, and advanced technology sectors.
SK Bioscience Co., Ltd. operates as a key biotechnology and vaccine-manufacturing subsidiary of SK discovery, which functions as the intermediate holding company under South Korea's massive SK Group conglomerate.
SK bioscience Co., Ltd. is publicly traded on the Korea Exchange under the official stock ticker symbol 302440.
SK Biopharmaceuticals, a prominent South Korean innovative healthcare and pharmaceutical enterprise listed on the Korea Exchange, maintains a market capitalization fluctuating around 4.2 billion to 4.5 billion US dollars.
SK Bioscience played a direct and notable role in the global response to the pandemic by developing Skycovione, which marked South Korea's first domestically produced COVID-19 vaccine utilizing advanced protein subunit technology.
SK Finance operates primarily as a non-banking financial company focusing on vehicle financing and micro, small, and medium enterprise loans.
SK Group is the second-largest chaebol (conglomerate) in South Korea, comprising over a hundred subsidiary and affiliate companies operating across advanced technology, energy, telecommunications, and biotechnology.
SK Life Sciences, operating as the United States subsidiary of SK Biopharmaceuticals, generates multi-million-dollar annual revenues driven primarily by the commercialization and prescription sales of its flagship central nervous system medications a...
SK Pharma generally refers to the pharmaceutical and life sciences business sectors managed under the broader umbrella of South Korea's SK Group, encompassing specialized corporate entities like SK Biopharmaceuticals and SK bioscience.